Company / Operating Margin
SAB Biotherapeutics, Inc. Operating Margin History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-3244.9%
FY2025
5-year range
-3244.9% / 37.2%
FY2021-FY2025
Trend
-90.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Margin has declined for 4 consecutive years, from 37.2% in FY2021 to -3244.9% in FY2025.
Based on SEC 10-K filings.
-3244.9% in FY2025 with a 3-year CAGR of -3222.9%.
Declined from -121.0% to -3244.9% over the past 2 years.
Operating Margin over time
Growth rates
- 3-Year Change
- -3222.9pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- SAB Biotherapeutics, Inc.'s operating margin has declined for 4 consecutive years.
- In FY2025, operating margin decreased 90.8% year-over-year.
- Peak operating margin was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -3244.9% | -90.8% |
| FY2024 | -1700.6% | -1305.8% |
| FY2023 | -121.0% | -449.9% |
| FY2022 | -22.0% | -159.1% |
| FY2021 | 37.2% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026